Oyster Therapeutics, formerly Kesmalea, closed a $60m Series A on Tuesday 10 November led by London's 4BIO Capital, with Eli Lilly joining as a new strategic investor1. Oyster makes protein degraders, drugs that tag a faulty protein for the cell's own disposal system, aimed at tau, the protein that tangles inside nerve cells in Alzheimer's disease.
Lilly put money into two British biotech rounds in five days, the other being T-Therapeutics' Series B, both times as a minority investor behind a specialist lead. A drugmaker buying in at Series A and Series B gets an early view of clinical data, and a seat near any later licensing talks, without setting the price. Licensing is where the money moves later: AstraZeneca paid C4X Discovery a milestone in September when a licensed compound entered its first human trial.
